# Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

> **NCT02595918** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Stage I Renal Cell Cancer AJCC v6 and v7
- Stage II Renal Cell Cancer AJCC v7
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **PROCEDURE:** Metastasectomy
- **PROCEDURE:** Nephrectomy
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02595918
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-19
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595918, "Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02595918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*